Catalent (CTLT) Receives New Coverage from Analysts at First Analysis
Several other research firms have also recently issued reports on CTLT. BidaskClub cut shares of Catalent from a buy rating to a hold rating in a research report on Tuesday, November 14th. Zacks Investment Research raised shares of Catalent from a hold rating to a strong-buy rating and set a $49.00 target price on the stock in a research report on Thursday, October 26th. ValuEngine raised shares of Catalent from a hold rating to a buy rating in a research report on Thursday, September 7th. Morgan Stanley raised shares of Catalent from an equal weight rating to an overweight rating and raised their target price for the stock from $29.00 to $48.00 in a research report on Thursday, September 21st. Finally, Needham & Company LLC reissued a hold rating on shares of Catalent in a research report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $44.44.
Shares of Catalent (NYSE:CTLT) opened at $41.66 on Friday. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49. Catalent has a 12-month low of $25.51 and a 12-month high of $43.39. The stock has a market cap of $5,550.87, a P/E ratio of 47.89, a P/E/G ratio of 2.69 and a beta of 1.41.
In other Catalent news, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total transaction of $7,189,365.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Uwe Roehrhoff acquired 7,500 shares of the company’s stock in a transaction dated Tuesday, November 21st. The shares were purchased at an average price of $39.22 per share, for a total transaction of $294,150.00. The disclosure for this purchase can be found here. Insiders own 1.70% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Catalent by 15.2% during the second quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock valued at $614,695,000 after purchasing an additional 2,316,849 shares during the period. Vanguard Group Inc. raised its stake in shares of Catalent by 3.8% during the second quarter. Vanguard Group Inc. now owns 10,119,431 shares of the company’s stock valued at $355,192,000 after purchasing an additional 369,526 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of Catalent during the second quarter valued at approximately $239,629,000. State Street Corp raised its stake in shares of Catalent by 10.7% during the second quarter. State Street Corp now owns 4,315,841 shares of the company’s stock valued at $151,488,000 after purchasing an additional 418,196 shares during the period. Finally, Earnest Partners LLC raised its stake in shares of Catalent by 0.5% during the third quarter. Earnest Partners LLC now owns 2,570,156 shares of the company’s stock valued at $102,601,000 after purchasing an additional 12,652 shares during the period. Institutional investors own 99.37% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Catalent (CTLT) Receives New Coverage from Analysts at First Analysis” was originally posted by Marea Informative and is the sole property of of Marea Informative. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.mareainformativa.com/2018/01/06/catalent-ctlt-receives-new-coverage-from-analysts-at-first-analysis.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.